Clinical Significance and Management of Hyponatremia in Liver Cirrhosis
Abstract
:1. Introduction
2. Search Strategy
3. Clinical Significance
3.1. Mortality
3.2. Hepatorenal Syndrome
3.3. Neurological Symptoms
3.4. Infections
3.5. Posttransplant Outcomes
4. Management of Hyponatremia in Cirrhosis
4.1. Diet and Lifestyle Changes
4.2. Transjugular Intrahepatic Portosystemic Shunt (TIPS)
4.3. Pharmacological Therapy
4.3.1. Vasoconstriction Therapy
4.3.2. Antidiuretic Hormone Antagonists
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Angeli, P.; Wong, F.; Watson, H.; Gines, P. Hyponatremia in cirrhosis: Results of a patient population survey. Hepatology 2006, 44, 1535–1542. [Google Scholar] [CrossRef] [PubMed]
- Gines, P.; Berl, T.; Bernardi, M.; Bichet, D.G.; Hamon, G.; Jimenez, W.; Liard, J.F.; Martin, P.Y.; Schrier, R.W. Hyponatremia in cirrhosis: From pathogenesis to treatment. Hepatology 1998, 28, 851–864. [Google Scholar] [CrossRef] [PubMed]
- Kim, W.R.; Biggins, S.W.; Kremers, W.K.; Wiesner, R.H.; Kamath, P.S.; Benson, J.T.; Edwards, E.; Therneau, T.M. Hyponatremia and mortality among patients on the liver-transplant waiting list. N. Engl. J. Med. 2008, 359, 1018–1026. [Google Scholar] [CrossRef] [PubMed]
- Verbrugge, F.H.; Steels, P.; Grieten, L.; Nijst, P.; Tang, W.H.; Mullens, W. Hyponatremia in acute decompensated heart failure: Depletion versus dilution. J. Am. Coll. Cardiol. 2015, 65, 480–492. [Google Scholar] [CrossRef]
- Adrogue, H.J.; Madias, N.E. The challenge of hyponatremia. J. Am. Soc. Nephrol. JASN 2012, 23, 1140–1148. [Google Scholar] [CrossRef]
- Angeli, P.; Bernardi, M.; Villanueva, C.; Francoz, C.; Mookerjee, R.P.; Trebicka, J.; Krag, A.; Laleman, W.; Gines, P. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. 2018, 69, 406–460. [Google Scholar] [CrossRef]
- Sahay, M.; Sahay, R. Hyponatremia: A practical approach. Indian. J. Endocrinol. Metab. 2014, 18, 760–771. [Google Scholar] [CrossRef]
- Vo, H.; Gosmanov, A.R.; Garcia-Rosell, M.; Wall, B.M. Pseudohyponatremia in acute liver disease. Am. J. Med. Sci. 2013, 345, 62–64. [Google Scholar] [CrossRef]
- Gines, P.; Guevara, M. Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. Hepatology 2008, 48, 1002–1010. [Google Scholar] [CrossRef]
- Melrose, W.D.; Bell, P.A.; Jupe, D.M.; Baikie, M.J. Alcohol-associated haemolysis in Zieve’s syndrome: A clinical and laboratory study of five cases. Clin. Lab. Haematol. 1990, 12, 159–167. [Google Scholar] [CrossRef]
- Porcel, A.; Diaz, F.; Rendon, P.; Macias, M.; Martin-Herrera, L.; Giron-Gonzalez, J.A. Dilutional hyponatremia in patients with cirrhosis and ascites. Arch. Intern. Med. 2002, 162, 323–328. [Google Scholar] [CrossRef]
- Cárdenas, A.; Solà, E.; Rodríguez, E.; Barreto, R.; Graupera, I.; Pavesi, M.; Saliba, F.; Welzel, T.M.; Martinez-Gonzalez, J.; Gustot, T.; et al. Hyponatremia influences the outcome of patients with acute-on-chronic liver failure: An analysis of the CANONIC study. Crit. Care 2014, 18, 700. [Google Scholar] [CrossRef] [PubMed]
- Costa, D.; Simbrunner, B.; Jachs, M.; Hartl, L.; Bauer, D.; Paternostro, R.; Schwabl, P.; Scheiner, B.; Stättermayer, A.F.; Pinter, M.; et al. Systemic Inflammation Increases across Distinct Stages of Advanced Chronic Liver Disease and Correlates with Decompensation and Mortality. J. Hepatol. 2021, 74, 819–828. [Google Scholar] [CrossRef] [PubMed]
- Wang, Y.W.; Huo, T.I.; Yang, Y.Y.; Hou, M.C.; Lee, P.C.; Lin, H.C.; Lee, F.Y.; Chi, C.W.; Lee, S.D. Correlation and comparison of the model for end-stage liver disease, portal pressure, and serum sodium for outcome prediction in patients with liver cirrhosis. J. Clin. Gastroenterol. 2007, 41, 706–712. [Google Scholar] [CrossRef] [PubMed]
- Maruyama, H.; Kondo, T.; Kiyono, S.; Sekimoto, T.; Takahashi, M.; Okugawa, H.; Yokosuka, O. Relationship and interaction between serum sodium concentration and portal hemodynamics in patients with cirrhosis. J. Gastroenterol. Hepatol. 2015, 30, 1635–1642. [Google Scholar] [CrossRef] [PubMed]
- Shaikh, S.; Mal, G.; Khalid, S.; Baloch, G.H.; Akbar, Y. Frequency of hyponatraemia and its influence on liver cirrhosis-related complications. J. Pak. Med. Assoc. 2010, 60, 116–120. [Google Scholar]
- Kim, J.H.; Lee, J.S.; Lee, S.H.; Bae, W.K.; Kim, N.H.; Kim, K.A.; Moon, Y.S. The association between the serum sodium level and the severity of complications in liver cirrhosis. Korean J. Intern. Med. 2009, 24, 106–112. [Google Scholar] [CrossRef] [PubMed]
- Miceli, G.; Calvaruso, V.; Casuccio, A.; Pennisi, G.; Licata, M.; Pintus, C.; Basso, M.G.; Velardo, M.; Daidone, M.; Amodio, E.; et al. Heart Rate Variability Is Associated with Disease Severity and Portal Hypertension in Cirrhosis. Hepatol. Commun. 2023, 7, e0050. [Google Scholar] [CrossRef]
- Mathur, S.; Gane, E.J.; McCall, J.L.; Plank, L.D. Serum sodium and hydration status predict transplant-free survival independent of MELD score in patients with cirrhosis. J. Gastroenterol. Hepatol. 2008, 23, 239–243. [Google Scholar] [CrossRef]
- Londono, M.C.; Cardenas, A.; Guevara, M.; Quinto, L.; de Las Heras, D.; Navasa, M.; Rimola, A.; Garcia-Valdecasas, J.C.; Arroyo, V.; Gines, P. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007, 56, 1283–1290. [Google Scholar] [CrossRef]
- Umemura, T.; Shibata, S.; Sekiguchi, T.; Kitabatake, H.; Nozawa, Y.; Okuhara, S.; Kimura, T.; Morita, S.; Komatsu, M.; Matsumoto, A.; et al. Serum sodium concentration is associated with increased risk of mortality in patients with compensated liver cirrhosis. Hepatol. Res. Off. J. Jpn. Soc. Hepatol. 2015, 45, 739–744. [Google Scholar] [CrossRef]
- Borroni, G.; Maggi, A.; Sangiovanni, A.; Cazzaniga, M.; Salerno, F. Clinical relevance of hyponatraemia for the hospital outcome of cirrhotic patients. Dig. Liver Dis. Off. J. Ital. Soc. Gastroenterol. Ital. Assoc. Study Liver 2000, 32, 605–610. [Google Scholar] [CrossRef] [PubMed]
- Heuman, D.M.; Abou-Assi, S.G.; Habib, A.; Williams, L.M.; Stravitz, R.T.; Sanyal, A.J.; Fisher, R.A.; Mihas, A.A. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004, 40, 802–810. [Google Scholar] [CrossRef] [PubMed]
- Bernasovská, G.; Hrušovský, S.; Štugelová, M.; Demeš, M.; Smetanová, V.; Žigrai, M. Hyponatremia-predictive mortality factor in hospitalized patients with hepatic cirrhosis. Lek. Obz. 2011, 60, 7–13. [Google Scholar]
- Ruf, A.E.; Kremers, W.K.; Chavez, L.L.; Descalzi, V.I.; Podesta, L.G.; Villamil, F.G. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 2005, 11, 336–343. [Google Scholar] [CrossRef]
- Biggins, S.W.; Kim, W.R.; Terrault, N.A.; Saab, S.; Balan, V.; Schiano, T.; Benson, J.; Therneau, T.; Kremers, W.; Wiesner, R.; et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006, 130, 1652–1660. [Google Scholar] [CrossRef]
- Luca, A.; Angermayr, B.; Bertolini, G.; Koenig, F.; Vizzini, G.; Ploner, M.; Peck-Radosavljevic, M.; Gridelli, B.; Bosch, J. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 2007, 13, 1174–1180. [Google Scholar] [CrossRef]
- Huo, T.I.; Wang, Y.W.; Yang, Y.Y.; Lin, H.C.; Lee, P.C.; Hou, M.C.; Lee, F.Y.; Lee, S.D. Model for end-stage liver disease score to serum sodium ratio index as a prognostic predictor and its correlation with portal pressure in patients with liver cirrhosis. Liver Int. Off. J. Int. Assoc. Study Liver 2007, 27, 498–506. [Google Scholar] [CrossRef]
- Silva Duarte Dos Santos, R.; Kieling, C.O.; Adami, M.R.; Guedes, R.R.; Vieira, S.M.G. Hypervolemic hyponatremia and transplant-free survival in children with cirrhosis due to biliary atresia. Pediatr. Transplant. 2020, 24, e13687. [Google Scholar] [CrossRef]
- Sharawey, M.A.; Shawky, E.M.; Ali, L.H.; Mohammed, A.A.; Hassan, H.A.; Fouad, Y.M. Cystatin C: A predictor of hepatorenal syndrome in patients with liver cirrhosis. Hepatol. Int. 2011, 5, 927–933. [Google Scholar] [CrossRef]
- Tyagi, P.; Sharma, P.; Sharma, B.C.; Puri, A.S.; Kumar, A.; Sarin, S.K. Prevention of hepatorenal syndrome in patients with cirrhosis and ascites: A pilot randomized control trial between pentoxifylline and placebo. Eur. J. Gastroenterol. Hepatol. 2011, 23, 210–217. [Google Scholar] [CrossRef]
- Gines, A.; Escorsell, A.; Gines, P.; Salo, J.; Jimenez, W.; Inglada, L.; Navasa, M.; Claria, J.; Rimola, A.; Arroyo, V.; et al. Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993, 105, 229–236. [Google Scholar]
- Ahn, H.S.; Kim, Y.S.; Kim, S.G.; Kim, H.K.; Min, S.K.; Jeong, S.W.; Jang, J.Y.; Lee, S.H.; Kim, H.S.; Kim, B.S.; et al. Cystatin C is a good predictor of hepatorenal syndrome and survival in patients with cirrhosis who have normal serum creatinine levels. Hepato-Gastroenterol. 2012, 59, 1168–1173. [Google Scholar] [CrossRef]
- Janicko, M.; Veseliny, E.; Abraldes, J.G.; Jarcuska, P. Serum sodium identifies patients with cirrhosis at high risk of hepatorenal syndrome. Z. Fur Gastroenterol. 2013, 51, 628–634. [Google Scholar] [CrossRef]
- Guevara, M.; Baccaro, M.E.; Torre, A.; Gomez-Anson, B.; Rios, J.; Torres, F.; Rami, L.; Monte-Rubio, G.C.; Martin-Llahi, M.; Arroyo, V.; et al. Hyponatremia is a risk factor of hepatic encephalopathy in patients with cirrhosis: A prospective study with time-dependent analysis. Am. J. Gastroenterol. 2009, 104, 1382–1389. [Google Scholar] [CrossRef] [PubMed]
- Bossen, L.; Gines, P.; Vilstrup, H.; Watson, H.; Jepsen, P. Serum sodium as a risk factor for hepatic encephalopathy in patients with cirrhosis and ascites. J. Gastroenterol. Hepatol. 2019, 34, 914–920. [Google Scholar] [CrossRef]
- Wunsch, E.; Naprawa, G.; Koziarska, D.; Milkiewicz, M.; Nowacki, P.; Milkiewicz, P. Serum natremia affects health-related quality of life in patients with liver cirrhosis: A prospective, single centre study. Ann. Hepatol. 2013, 12, 448–455. [Google Scholar] [PubMed]
- Ahluwalia, V.; Wade, J.B.; Thacker, L.; Kraft, K.A.; Sterling, R.K.; Stravitz, R.T.; Fuchs, M.; Bouneva, I.; Puri, P.; Luketic, V.; et al. Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis. J. Hepatol. 2013, 59, 467–473. [Google Scholar] [CrossRef] [PubMed]
- Watson, H.; Guevara, M.; Vilstrup, H.; Gines, P. Improvement of hyponatremia in cirrhosis is associated with improved complex information processing. J. Gastroenterol. Hepatol. 2019, 34, 1999–2003. [Google Scholar] [CrossRef]
- Bruns, T.; Zimmermann, H.W.; Stallmach, A. Risk factors and outcome of bacterial infections in cirrhosis. World J. Gastroenterol. WJG 2014, 20, 2542–2554. [Google Scholar] [CrossRef] [PubMed]
- Arvaniti, V.; D’Amico, G.; Fede, G.; Manousou, P.; Tsochatzis, E.; Pleguezuelo, M.; Burroughs, A.K. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis. Gastroenterology 2010, 139, 1246–1256.e5. [Google Scholar] [CrossRef]
- Pereira, G.; Guevara, M.; Fagundes, C.; Sola, E.; Rodriguez, E.; Fernandez, J.; Pavesi, M.; Arroyo, V.; Gines, P. Renal failure and hyponatremia in patients with cirrhosis and skin and soft tissue infection. A retrospective study. J. Hepatol. 2012, 56, 1040–1046. [Google Scholar] [CrossRef]
- Follo, A.; Llovet, J.M.; Navasa, M.; Planas, R.; Forns, X.; Francitorra, A.; Rimola, A.; Gassull, M.A.; Arroyo, V.; Rodes, J. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: Incidence, clinical course, predictive factors and prognosis. Hepatology 1994, 20, 1495–1501. [Google Scholar] [CrossRef] [PubMed]
- Abbasoglu, O.; Goldstein, R.M.; Vodapally, M.S.; Jennings, L.W.; Levy, M.F.; Husberg, B.S.; Klintmalm, G.B. Liver transplantation in hyponatremic patients with emphasis on central pontine myelinolysis. Clin. Transplant. 1998, 12, 263–269. [Google Scholar] [PubMed]
- Lee, J.; Kim, D.K.; Lee, J.W.; Oh, K.H.; Oh, Y.K.; Na, K.Y.; Kim, Y.S.; Han, J.S.; Suh, K.S.; Joo, K.W. Rapid correction rate of hyponatremia as an independent risk factor for neurological complication following liver transplantation. Tohoku J. Exp. Med. 2013, 229, 97–105. [Google Scholar] [PubMed]
- Karapanagiotou, A.; Kydona, C.; Papadopoulos, S.; Dimitriadis, C.; Giasnetsova, T.; Rempelakos, G.; Passakiotou, M.; Fouzas, I.; Papanikolaou, V.; Gritsi-Gerogianni, N. The effect of hyponatremia on the outcome of patients after orthotopic liver transplantation. Transplant. Proc. 2012, 44, 2724–2726. [Google Scholar] [CrossRef]
- Londono, M.C.; Guevara, M.; Rimola, A.; Navasa, M.; Taura, P.; Mas, A.; Garcia-Valdecasas, J.C.; Arroyo, V.; Gines, P. Hyponatremia impairs early posttransplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology 2006, 130, 1135–1143. [Google Scholar] [CrossRef]
- Dawwas, M.F.; Lewsey, J.D.; Neuberger, J.M.; Gimson, A.E. The impact of serum sodium concentration on mortality after liver transplantation: A cohort multicenter study. Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 2007, 13, 1115–1124. [Google Scholar] [CrossRef]
- Wang, P.; Huang, G.; Tam, N.; Wu, C.; Fu, S.; Hughes, B.P.; Wu, L.; He, X. Influence of preoperative sodium concentration on outcome of patients with hepatitis B virus cirrhosis after liver transplantation. Eur. J. Gastroenterol. Hepatol. 2016, 28, 1210–1215. [Google Scholar] [CrossRef] [PubMed]
- Manolakopoulos, S.; Triantos, C.; Theodoropoulos, J.; Vlachogiannakos, J.; Kougioumtzan, A.; Papatheodoridis, G.; Tzourmakliotis, D.; Karamanolis, D.; Burroughs, A.K.; Archimandritis, A.; et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J. Hepatol. 2009, 51, 468–474. [Google Scholar] [CrossRef]
- Alukal, J.J.; John, S.; Thuluvath, P.J. Hyponatremia in Cirrhosis: An Update. Am. J. Gastroenterol. 2020, 115, 1775–1785. [Google Scholar] [CrossRef] [PubMed]
- Cardenas, A.; Riggio, O. Correction of hyponatraemia in cirrhosis: Treating more than a number! J. Hepatol. 2015, 62, 13–14. [Google Scholar] [CrossRef]
- Biggins, S.W.; Angeli, P.; Garcia-Tsao, G.; Ginès, P.; Ling, S.C.; Nadim, M.K.; Wong, F.; Kim, W.R. Diagnosis, Evaluation, and Management of Ascites, Spontaneous Bacterial Peritonitis and Hepatorenal Syndrome: 2021 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology 2021, 74, 1014–1048. [Google Scholar] [CrossRef]
- European Association for the Study of the Liver. EASL clinical practice guidelines on the management of ascites, spontaneous bacterial peritonitis, and hepatorenal syndrome in cirrhosis. J. Hepatol. 2010, 53, 397–417. [Google Scholar] [CrossRef]
- Yu, C.; Sharma, N.; Saab, S. Hyponatremia: Clinical associations, prognosis, and treatment in cirrhosis. Exp. Clin. Transplant. Off. J. Middle East. Soc. Organ. Transplant. 2013, 11, 3–11. [Google Scholar]
- Sigal, S.H.; Amin, A.; Chiodo, J.A., 3rd; Sanyal, A. Management Strategies and Outcomes for Hyponatremia in Cirrhosis in the Hyponatremia Registry. Can. J. Gastroenterol. Hepatol. 2018, 2018, 1579508. [Google Scholar] [CrossRef] [PubMed]
- Gines, P.; Wong, F.; Watson, H.; Milutinovic, S.; del Arbol, L.R.; Olteanu, D.; Hypo, C.A.T.S.I. Effects of satavaptan, a selective vasopressin V(2) receptor antagonist, on ascites and serum sodium in cirrhosis with hyponatremia: A randomized trial. Hepatology 2008, 48, 204–213. [Google Scholar] [CrossRef]
- Gerbes, A.L.; Gulberg, V.; Gines, P.; Decaux, G.; Gross, P.; Gandjini, H.; Djian, J. Therapy of hyponatremia in cirrhosis with a vasopressin receptor antagonist: A randomized double-blind multicenter trial. Gastroenterology 2003, 124, 933–939. [Google Scholar] [CrossRef]
- Bichet, D.G.; Groves, B.M.; Schrier, R.W. Mechanisms of improvement of water and sodium excretion by immersion in decompensated cirrhotic patients. Kidney Int. 1983, 24, 788–794. [Google Scholar]
- Schrier, R.W. Renin-angiotensin in preascitic cirrhosis: Evidence for primary peripheral arterial vasodilatation. Gastroenterology 1998, 115, 489–491. [Google Scholar] [CrossRef]
- Senousy, B.-E. Evaluation and management of patients with refractory ascites. World J. Gastroenterol. 2009, 15, 67–80. [Google Scholar] [CrossRef] [PubMed]
- Rossle, M.; Gerbes, A.L. TIPS for the treatment of refractory ascites, hepatorenal syndrome and hepatic hydrothorax: A critical update. Gut 2010, 59, 988–1000. [Google Scholar] [CrossRef] [PubMed]
- Jalan, R.; Redhead, D.N.; Thomas, H.W.; Henderson, N.; O’Rourke, K.; Dillon, J.F.; Williams, B.C.; Hayes, P.C. Mechanisms of changes in renal handling of sodium following transjugular intrahepatic portal systemic stent-shunt (TIPSS). Eur. J. Gastroenterol. Hepatol. 1996, 8, 1111–1116. [Google Scholar] [CrossRef] [PubMed]
- Quiroga, J.; Sangro, B.; Nunez, M.; Bilbao, I.; Longo, J.; Garcia-Villarreal, L.; Zozaya, J.M.; Betes, M.; Herrero, J.I.; Prieto, J. Transjugular intrahepatic portal-systemic shunt in the treatment of refractory ascites: Effect on clinical, renal, humoral, and hemodynamic parameters. Hepatology 1995, 21, 986–994. [Google Scholar] [PubMed]
- Wong, F.; Blendis, L. Transjugular intrahepatic portosystemic shunt for refractory ascites: Tipping the sodium balance. Hepatology 1995, 22, 358–364. [Google Scholar] [CrossRef] [PubMed]
- Wong, F.; Sniderman, K.; Liu, P.; Allidina, Y.; Sherman, M.; Blendis, L. Transjugular intrahepatic portosystemic stent shunt: Effects on hemodynamics and sodium homeostasis in cirrhosis and refractory ascites. Ann. Intern. Med. 1995, 122, 816–822. [Google Scholar] [CrossRef] [PubMed]
- Allegretti, A.S.; Ortiz, G.; Cui, J.; Wenger, J.; Bhan, I.; Chung, R.T.; Thadhani, R.I.; Irani, Z. Changes in Kidney Function After Transjugular Intrahepatic Portosystemic Shunts Versus Large-Volume Paracentesis in Cirrhosis: A Matched Cohort Analysis. Am. J. Kidney Dis. 2016, 68, 381–391. [Google Scholar] [CrossRef]
- Ginès, P.; Uriz, J.; Calahorra, B.; Garcia–Tsao, G.; Kamath, P.S.; Del Arbol, L.R.; Planas, R.; Bosch, J.; Arroyo, V.; Rodés, J. Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology 2002, 123, 1839–1847. [Google Scholar] [CrossRef]
- Mandorfer, M.; Bota, S.; Schwabl, P.; Bucsics, T.; Pfisterer, N.; Kruzik, M.; Hagmann, M.; Blacky, A.; Ferlitsch, A.; Sieghart, W.; et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 2014, 146, 1680–1690.e1. [Google Scholar] [CrossRef]
- Gross, P. Clinical management of SIADH. Ther. Adv. Endocrinol. Metab. 2012, 3, 61–73. [Google Scholar] [CrossRef]
- McCormick, P.A.; Mistry, P.; Kaye, G.; Burroughs, A.K.; McIntyre, N. Intravenous albumin infusion is an effective therapy for hyponatraemia in cirrhotic patients with ascites. Gut 1990, 31, 204–207. [Google Scholar] [CrossRef]
- Jalan, R.; Mookerjee, R.; Cheshire, L.; Williams, R.; Davies, N. [232] Albumin Infusion for Severe Hyponatremia in Patients with Refractory Ascites: A Randomized Clinical Trial. J. Hepatol. 2007, 46, S95. [Google Scholar] [CrossRef]
- Bai, Z.; Xu, W.; Chai, L.; Zheng, X.; Mendez-Sanchez, N.; Philips, C.A.; Cheng, G.; Qi, X. Effects of Short-Term Human Albumin Infusion for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis. J. Clin. Med. 2022, 12, 107. [Google Scholar] [CrossRef] [PubMed]
- Bajaj, J.S.; Tandon, P.; O’Leary, J.G.; Biggins, S.W.; Wong, F.; Kamath, P.S.; Garcia-Tsao, G.; Maliakkal, B.; Lai, J.C.; Fallon, M.; et al. The Impact of Albumin Use on Resolution of Hyponatremia in Hospitalized Patients With Cirrhosis. Am. J. Gastroenterol. 2018, 113, 1339. [Google Scholar] [CrossRef] [PubMed]
- Bai, Z.; Wang, L.; Lin, H.; Tacke, F.; Cheng, G.; Qi, X. Use of Human Albumin Administration for the Prevention and Treatment of Hyponatremia in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis. J. Clin. Med. 2022, 11, 5928. [Google Scholar] [CrossRef] [PubMed]
- Zaccherini, G.; Baldassarre, M.; Tufoni, M.; Nardelli, S.; Piano, S.; Alessandria, C.; Neri, S.; Foschi, F.G.; Levantesi, F.; Bedogni, G.; et al. Correction and Prevention of Hyponatremia in Patients With Cirrhosis and Ascites: Post Hoc Analysis of the ANSWER Study Database. Am. J. Gastroenterol. 2023, 118, 168–173. [Google Scholar] [CrossRef]
- Decaux, G.; Mols, P.; Cauchie, P.; Flamion, B.; Delwiche, F. Treatment of hyponatremic cirrhosis with ascites resistant to diuretics by urea. Nephron 1986, 44, 337–343. [Google Scholar] [CrossRef] [PubMed]
- Raza, M.A.; Qureshi, U.F.; Humayoun, M.A.; Waseem, T.; Akram, J. Effect of intravenous mannitol in mobilization of resistant cirrhotic ascites. Eur. J. Gastroenterol. Hepatol. 2011, 23, 184–188. [Google Scholar] [CrossRef] [PubMed]
- Kang, Y.J.; Bae, E.J.; Hwang, K.; Jeon, D.H.; Jang, H.N.; Cho, H.S.; Chang, S.H.; Park, D.J. Initial serum sodium concentration determines the decrease in sodium level after terlipressin administration in patients with liver cirrhosis. SpringerPlus 2013, 2, 519. [Google Scholar] [CrossRef] [PubMed]
- Sola, E.; Lens, S.; Guevara, M.; Martin-Llahi, M.; Fagundes, C.; Pereira, G.; Pavesi, M.; Fernandez, J.; Gonzalez-Abraldes, J.; Escorsell, A.; et al. Hyponatremia in patients treated with terlipressin for severe gastrointestinal bleeding due to portal hypertension. Hepatology 2010, 52, 1783–1790. [Google Scholar] [CrossRef] [PubMed]
- Jarčuška, P.; Beňa, L.; Timková, A.; Veseliny, E.; Janičko, M. Hepatorenal syndrome in patients with acute alcoholic hepatitis. Ceska A Slov. Gastroenterol. A Hepatol. 2012, 66, 101–108. [Google Scholar]
- Duvoux, C.; Zanditenas, D.; Hezode, C.; Chauvat, A.; Monin, J.L.; Roudot-Thoraval, F.; Mallat, A.; Dhumeaux, D. Effects of noradrenalin and albumin in patients with type I hepatorenal syndrome: A pilot study. Hepatology 2002, 36, 374–380. [Google Scholar] [CrossRef]
- Tavakkoli, H.; Yazdanpanah, K.; Mansourian, M. Noradrenalin versus the combination of midodrine and octreotide in patients with hepatorenal syndrome: Randomized clinical trial. Int. J. Prev. Med. 2012, 3, 764–769. [Google Scholar] [PubMed]
- Patel, S.; Nguyen, D.S.; Rastogi, A.; Nguyen, M.K.; Nguyen, M.K. Treatment of Cirrhosis-Associated Hyponatremia with Midodrine and Octreotide. Front. Med. 2017, 4, 17. [Google Scholar] [CrossRef]
- Singh, V.; Dhungana, S.P.; Singh, B.; Vijayverghia, R.; Nain, C.K.; Sharma, N.; Bhalla, A.; Gupta, P.K. Midodrine in patients with cirrhosis and refractory or recurrent ascites: A randomized pilot study. J. Hepatol. 2012, 56, 348–354. [Google Scholar] [CrossRef]
- Solà, E.; Solé, C.; Simón-Talero, M.; Martín-Llahí, M.; Castellote, J.; Garcia-Martínez, R.; Moreira, R.; Torrens, M.; Márquez, F.; Fabrellas, N.; et al. Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial. J. Hepatol. 2018, 69, 1250–1259. [Google Scholar] [CrossRef] [PubMed]
- Cardenas, A. Nitric oxide inhibition in cirrhosis and ascites. Am. J. Gastroenterol. 2003, 98, 1666–1667. [Google Scholar] [CrossRef] [PubMed]
- Troyer, A.; Pilloy, W.; Broeckaert, I.; Demanet, J.C. Letter: Demeclocycline treatment of water retention in cirrhosis. Ann. Intern. Med. 1976, 85, 336–337. [Google Scholar] [CrossRef] [PubMed]
- Gadano, A.; Moreau, R.; Pessione, F.; Trombino, C.; Giuily, N.; Sinnassamy, P.; Valla, D.; Lebrec, D. Aquaretic effects of niravoline, a kappa-opioid agonist, in patients with cirrhosis. J. Hepatol. 2000, 32, 38–42. [Google Scholar] [CrossRef]
- Schrier, R.W.; Gross, P.; Gheorghiade, M.; Berl, T.; Verbalis, J.G.; Czerwiec, F.S.; Orlandi, C.; Investigators, S. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N. Engl. J. Med. 2006, 355, 2099–2112. [Google Scholar] [CrossRef]
- Cardenas, A.; Gines, P.; Marotta, P.; Czerwiec, F.; Oyuang, J.; Guevara, M.; Afdhal, N.H. Tolvaptan, an oral vasopressin antagonist, in the treatment of hyponatremia in cirrhosis. J. Hepatol. 2012, 56, 571–578. [Google Scholar] [CrossRef]
- Okita, K.; Sakaida, I.; Okada, M.; Kaneko, A.; Chayama, K.; Kato, M.; Sata, M.; Yoshihara, H.; Ono, N.; Murawaki, Y. A multicenter, open-label, dose-ranging study to exploratively evaluate the efficacy, safety, and dose-response of tolvaptan in patients with decompensated liver cirrhosis. J. Gastroenterol. 2010, 45, 979–987. [Google Scholar] [CrossRef] [PubMed]
- Sakaida, I.; Kawazoe, S.; Kajimura, K.; Saito, T.; Okuse, C.; Takaguchi, K.; Okada, M.; Okita, K.; Group, A.-D.S. Tolvaptan for improvement of hepatic edema: A phase 3, multicenter, randomized, double-blind, placebo-controlled trial. Hepatol. Res. Off. J. Jpn. Soc. Hepatol. 2014, 44, 73–82. [Google Scholar] [CrossRef]
- Iwasa, M.; Ishihara, T.; Hasegawa, H.; Takei, Y. Cirrhosis-related hyponatremia and the role of tolvaptan. Hepatol. Res. Off. J. Jpn. Soc. Hepatol. 2015, 45, E163–E165. [Google Scholar] [CrossRef]
- Hayashi, M.; Abe, K.; Fujita, M.; Okai, K.; Takahashi, A.; Ohira, H. Association between the Serum Sodium Levels and the Response to Tolvaptan in Liver Cirrhosis Patients with Ascites and Hyponatremia. Intern. Med. 2018, 57, 2451–2458. [Google Scholar] [CrossRef]
- Pose, E.; Sola, E.; Piano, S.; Gola, E.; Graupera, I.; Guevara, M.; Cardenas, A.; Angeli, P.; Gines, P. Limited Efficacy of Tolvaptan in Patients with Cirrhosis and Severe Hyponatremia: Real-Life Experience. Am. J. Med. 2017, 130, 372–375. [Google Scholar] [CrossRef]
- Zeltser, D.; Rosansky, S.; van Rensburg, H.; Verbalis, J.G.; Smith, N.; Conivaptan Study, G. Assessment of the efficacy and safety of intravenous conivaptan in euvolemic and hypervolemic hyponatremia. Am. J. Nephrol. 2007, 27, 447–457. [Google Scholar] [CrossRef]
- O’Leary, J.G.; Davis, G.L. Conivaptan increases serum sodium in hyponatremic patients with end-stage liver disease. Liver Transplant. Off. Publ. Am. Assoc. Study Liver Dis. Int. Liver Transplant. Soc. 2009, 15, 1325–1329. [Google Scholar] [CrossRef]
- Wong, F.; Blei, A.T.; Blendis, L.M.; Thuluvath, P.J. A vasopressin receptor antagonist (VPA-985) improves serum sodium concentration in patients with hyponatremia: A multicenter, randomized, placebo-controlled trial. Hepatology 2003, 37, 182–191. [Google Scholar] [CrossRef]
- Abraham, W.T.; Aranda, J.M.; Boehmer, J.P.; Elkayam, U.; Gilbert, E.M.; Gottlieb, S.S.; Hasenfuss, G.; Kukin, M.; Lowes, B.D.; O’Connell, J.B.; et al. Rationale and design of the treatment of hyponatremia based on lixivaptan in NYHA class III/IV cardiac patient evaluation (THE BALANCE) study. Clin. Transl. Sci. 2010, 3, 249–253. [Google Scholar] [CrossRef]
- Bowman, B.T.; Rosner, M.H. Lixivaptan—An evidence-based review of its clinical potential in the treatment of hyponatremia. Core Evid. 2013, 8, 47–56. [Google Scholar] [CrossRef] [PubMed]
- Wong, F.; Watson, H.; Gerbes, A.; Vilstrup, H.; Badalamenti, S.; Bernardi, M.; Gines, P.; Satavaptan Investigators, G. Satavaptan for the management of ascites in cirrhosis: Efficacy and safety across the spectrum of ascites severity. Gut 2012, 61, 108–116. [Google Scholar] [CrossRef] [PubMed]
- Dahl, E.; Gluud, L.L.; Kimer, N.; Krag, A. Meta-analysis: The safety and efficacy of vaptans (tolvaptan, satavaptan and lixivaptan) in cirrhosis with ascites or hyponatraemia. Aliment. Pharmacol. Ther. 2012, 36, 619–626. [Google Scholar] [CrossRef] [PubMed]
- Torres, V.E.; Chapman, A.B.; Devuyst, O.; Gansevoort, R.T.; Grantham, J.J.; Higashihara, E.; Perrone, R.D.; Krasa, H.B.; Ouyang, J.; Czerwiec, F.S.; et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 2012, 367, 2407–2418. [Google Scholar] [CrossRef]
- SAMSCA [Package Insert]. Otsuka America Pharmaceutical, Inc.: Rockville, MD, USA, 2014. Available online: https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022275s014lbl.pdf (accessed on 1 April 2017).
- Kwo, P.Y. Management of hyponatremia in clinical hepatology practice. Curr. Gastroenterol. Rep. 2014, 16, 382. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Janičko, M.; Dražilová, S.; Gazda, J.; Tomáš, M.; Kučera, M.; Šuchová, Ž.; Jarčuška, P. Clinical Significance and Management of Hyponatremia in Liver Cirrhosis. Gastroenterol. Insights 2023, 14, 446-462. https://doi.org/10.3390/gastroent14040033
Janičko M, Dražilová S, Gazda J, Tomáš M, Kučera M, Šuchová Ž, Jarčuška P. Clinical Significance and Management of Hyponatremia in Liver Cirrhosis. Gastroenterology Insights. 2023; 14(4):446-462. https://doi.org/10.3390/gastroent14040033
Chicago/Turabian StyleJaničko, Martin, Sylvia Dražilová, Jakub Gazda, Martin Tomáš, Martin Kučera, Želmíra Šuchová, and Peter Jarčuška. 2023. "Clinical Significance and Management of Hyponatremia in Liver Cirrhosis" Gastroenterology Insights 14, no. 4: 446-462. https://doi.org/10.3390/gastroent14040033